HomeCompareMNKPF vs QYLD

MNKPF vs QYLD: Dividend Comparison 2026

MNKPF yields 11.59% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MNKPF wins by $17.6K in total portfolio value
10 years
MNKPF
MNKPF
● Live price
11.59%
Share price
$17.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.0K
Annual income
$2,392.79
Full MNKPF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — MNKPF vs QYLD

📍 MNKPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNKPFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNKPF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNKPF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNKPF
Annual income on $10K today (after 15% tax)
$985.51/yr
After 10yr DRIP, annual income (after tax)
$2,033.87/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $2,776.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNKPF + QYLD for your $10,000?

MNKPF: 50%QYLD: 50%
100% QYLD50/50100% MNKPF
Portfolio after 10yr
$34.2K
Annual income
$4,026.06/yr
Blended yield
11.77%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNKPF buys
0
QYLD buys
0
No recent congressional trades found for MNKPF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNKPFQYLD
Forward yield11.59%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$43.0K$25.4K
Annual income after 10y$2,392.79$5,659.31
Total dividends collected$17.6K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: MNKPF vs QYLD ($10,000, DRIP)

YearMNKPF PortfolioMNKPF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$11,859$1,159.42$10,352$1,192.36+$1.5KMNKPF
2$13,975$1,285.05$10,830$1,347.57+$3.1KMNKPF
3$16,368$1,415.19$11,460$1,539.07+$4.9KMNKPF
4$19,063$1,549.12$12,275$1,777.84+$6.8KMNKPF
5$22,083$1,686.15$13,323$2,078.95+$8.8KMNKPF
6$25,455$1,825.53$14,667$2,463.34+$10.8KMNKPF
7$29,203$1,966.57$16,396$2,960.57+$12.8KMNKPF
8$33,356$2,108.56$18,631$3,612.97+$14.7KMNKPF
9$37,942$2,250.84$21,548$4,482.15+$16.4KMNKPF
10$42,991$2,392.79$25,398$5,659.31+$17.6KMNKPF

MNKPF vs QYLD: Complete Analysis 2026

MNKPFStock

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.

Full MNKPF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this MNKPF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNKPF vs SCHDMNKPF vs JEPIMNKPF vs OMNKPF vs KOMNKPF vs MAINMNKPF vs XYLDMNKPF vs JEPQMNKPF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.